Hims & Hers Health (NYSE:HIMS) Sets New 1-Year High – What’s Next?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) hit a new 52-week high during trading on Wednesday . The company traded as high as $35.02 and last traded at $34.77, with a volume of 5424326 shares. The stock had previously closed at $30.68.

Wall Street Analyst Weigh In

HIMS has been the subject of several research analyst reports. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.71.

Hims & Hers Health Stock Up 1.6 %

The firm has a market capitalization of $6.81 billion, a price-to-earnings ratio of 79.02 and a beta of 1.06. The firm’s 50 day moving average is $20.85 and its 200 day moving average is $19.44.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.04) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total value of $169,491.40. Following the completion of the sale, the chief financial officer now owns 181,469 shares of the company’s stock, valued at approximately $2,649,447.40. The trade was a 6.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,153,519 shares of company stock worth $24,486,721. 17.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. acquired a new position in Hims & Hers Health during the 3rd quarter worth $604,000. Carnegie Investment Counsel acquired a new position in Hims & Hers Health during the 3rd quarter worth $5,531,000. Royce & Associates LP lifted its position in Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Versor Investments LP acquired a new position in Hims & Hers Health during the 3rd quarter worth $634,000. Finally, International Assets Investment Management LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth $6,790,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.